Zentalis Pharmaceuticals, Inc.ZNTLNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank77
3Y CAGR-67.8%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
-67.8%/yr
Quarterly compound
Percentile
P77
Within normal range
vs 3Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 0.68% |
| Q2 2025 | 44.34% |
| Q1 2025 | -1.70% |
| Q4 2024 | -18.21% |
| Q3 2024 | 54.51% |
| Q2 2024 | -976.81% |
| Q1 2024 | 116.53% |
| Q4 2023 | -9.71% |
| Q3 2023 | 50.65% |
| Q2 2023 | -78.00% |
| Q1 2023 | -15.00% |
| Q4 2022 | -1.05% |
| Q3 2022 | 20.42% |
| Q2 2022 | -15.71% |
| Q1 2022 | -18.01% |
| Q4 2021 | -1094.44% |
| Q3 2021 | 92.32% |
| Q2 2021 | -9.36% |
| Q1 2021 | -23.81% |
| Q4 2020 | -16.63% |
| Q3 2020 | -28.66% |
| Q2 2020 | -66.54% |
| Q1 2020 | -11.17% |
| Q4 2019 | -17.51% |
| Q3 2019 | -17.90% |
| Q2 2019 | -25.49% |
| Q1 2019 | 0.00% |